Another highly selective MET inhibitor, bozitinib (also known as PLB-1001 or vebreltinib, Figure 4), exhibits blood–brain barrier permeability and has shown effective inhibition of MET-driven glioma progression in both cell lines and xenograft models [85]. This evidence concerns the gene MET and central nervous system cancer.